Appl. No. 10/743,909 Response dated 8/11/2005 Reply to Final Office Action of 6/3/2005

Listing of claims:

Claims 1-36 (Canceled)

37. (Currently amended) A compound of the formula I:

wherein

R³, R⁵ and R⁶ are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxyl, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino, and –NR¹¹R¹² where R¹¹ and R¹² are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl or, R¹¹ and R¹², together with the nitrogen to which they are attached, combined form a five- or six- member heteroalicyclic ring;

R⁷ is hydrogen;

R⁴ is hydrogen or halo;

R1' is hydrogen or methyl;

 $\ensuremath{\text{R}^{8}}$ and $\ensuremath{\text{R}^{10}}$ are independently unsubstituted lower alkyl;

 R^9 is $-C(=O)NHR^{13}$ wherein R^{13} is lower alkyl substituted with amino or heteroalicyclic and optionally substituted with hydroxy; and

R3-and R4-are lower alkyl optionally substituted hydroxyl; or

R^{3'} and R^{4'}, together with the nitrogen atom to which they are attached, form a ring selected from the group consisting of an unsubstituted pyrrolidin-1yl, -2-(S)-hydroxymethylpyrrolidin-1-yl, 2-(S)-carboxy-pyrrolidin-1-yl, piperazin-1-yl, and 4-methylpiperazin-1-yl; or

R³⁻-and R⁴⁻ together with the nitrogen atom to which they are attached form a heteroaryl ring selected from the group consisting of pyrro-1-yl, pyridin-1-yl, oxazol-3-yl, isoxazol-2-yl, pyrazin-1-yl, pyradizin-1-yl, quinolin-1-yl, and imidazol-1-yl.

38. (Previously presented) The compound of claim 37, wherein R³, R⁵ and R⁶ are hydrogen.

Appl. No. 10/743,909 Response dated 8/11/2005 Reply to Final Office Action of 6/3/2005

- 39. (Previously presented) The compound of claim 37, wherein R⁴ is hydrogen or fluoro.
- 40. (Previously presented) The compound of claim 37, wherein R1' is hydrogen.
- 41. (Previously presented) The compound of claim 37, wherein R⁸ and R¹⁰ are each methyl. Claims 42-43. (Canceled)
- 44. (Previously presented) The compound of claim 37, wherein R⁹ is (2-diethylaminoethyl)-aminocarbonyl, (2-ethylaminoethyl)aminocarbonyl, 3-(morpholin-4-yl)propyl-aminocarbonyl or 3-(morpholin-4-yl)-2-hydroxypropylaminocarbonyl.
- 45. (Previously presented) The compound of claim 37 wherein R⁹ is (2-diethylaminoethyl)-aminocarbonyl or 3-(morpholin-4-yl)-2-hydroxypropylaminocarbonyl.
- 46. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier or exipient and the compound of claim 37.

Claims 47-53 (Cancelled)